IP Library Granted Patent US 9,895,437
Granted Patent B2
US 9,895,437 · App. 13/449,596 · Granted Feb 20, 2018

Aluminum compounds for use in therapeutics and vaccines

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,895,437
App. No.
13/449,596
Granted
Feb 20, 2018
Kind
B2
Abstract

The invention relates to means and methods for preparing aqueous composition comprising aluminum and a protein said composition comprising less than 700 ppm heavy metal on the basis of weight with respect to the aluminum content. The invention further relates to aqueous compositions comprising a protein and an aluminum-salt, said composition comprising less than 350 ppb heavy metal based on the weight of the aqueous composition.

Claims (18)

1. An aqueous composition comprising a Japanese Encephalitis Virus (JEV) protein and an aluminum salt, wherein the aluminum salt is selected to provide an aqueous composition comprising less than 3 ppb Cu based on the weight of the aqueous composition.

2. The aqueous composition according to claim 1 , which has been stored at temperatures higher than 20° C. for at least 1 month.

3. The aqueous composition according to claim 1 , comprising less than 350 ppb heavy metal, wherein said heavy metal is selected from Ni, W, Co, Os, Ru, Cd, Ag, Fe, V, Cr, Pb, Rb and Mo.

4. The aqueous composition according to claim 1 , comprising less than 350 ppb heavy metal, wherein said heavy metal is selected from Ni, W, Co, Os, Ru, Cd, Ag, Fe and V.

5. The aqueous composition according to claim 1 , comprising less than 350 ppb heavy metal, wherein said heavy metal is Ni.

6. The aqueous composition according to claim 1 , comprising less than 350 ppb heavy metal, wherein said heavy metal is present in ionic form.

7. The aqueous composition according to claim 1 , wherein the aluminum salt is aluminum hydroxide (Al(OH)3) or aluminum phosphate (AlPO4).

8. The aqueous composition according to claim 1 , wherein the aluminum salt is aluminum hydroxide (Al(OH)3).

9. The aqueous composition according to claim 1 , further comprising a reactive compound selected from the group consisting of a redox active compound, a radical building compound, a stabilizing compound and a combination of any thereof.

10. The aqueous composition according to claim 1 , further comprising a reactive compound selected from the group consisting of formaldehyde, ethanol, chloroform, trichloroethylene, acetone, polyethylene glycol tert-octylphenyl ether, deoxycholate, diethylpyrocarbonate, sulphite, Na2S2O5, beta-proprio-lacton, polysorbate optionally Polysorbate 20 or Polysorbate 80, O2, phenol, poloxamer type copolymers, and a combination of any thereof.

11. The aqueous composition according to claim 1 , comprising between 5 μg/ml and 50 mg/ml aluminum.

12. The aqueous composition according to claim 1 , comprising between 50 m/ml and 5 mg/ml aluminum.

13. The aqueous composition according to claim 1 , comprising between 5 ppb and 250 ppb Fe based on the weight of the aqueous composition.

14. The aqueous composition according to claim 1 , comprising less than 40 ppb Ni based on the weight of the aqueous composition.

15. The aqueous composition according to claim 1 , wherein said protein is protein within formaldehyde inactivated virus particles.

16. The aqueous composition according to claim 1 , further comprising sulphite.

17. A JEV vaccine comprising the aqueous composition according to claim 1 .

18. The aqueous composition according to claim 1 , wherein said composition comprises less than 2.5 ppb Cu based on the weight of the aqueous composition.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: VALNEVA AUSTRIA GMBH; VALNEVA SE; VALNEVA USA, INC.
Reel/Frame 073516/0522 →
PATENT SECURITY AGREEMENT Recorded Oct 20, 2025
From: VALNEVA AUSTRIA GMBH; VALNEVA SE; VALNEVA SWEDEN AB
To: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
Reel/Frame 073164/0032 →
SECURITY INTEREST Recorded Mar 4, 2020
From: VALNEVA SE; VALNEVA USA, INC.; VALNEVA AUSTRIA GMBH
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 052016/0745 →
CHANGE OF NAME Recorded Apr 10, 2014
From: INTERCELL AUSTRIA AG
To: VALNEVA AUSTRIA GMBH
Reel/Frame 032642/0164 →
ASSET TRANSFER AGREEMENT Recorded Apr 10, 2014
From: INTERCELL AG
To: INTERCELL AUSTRIA AG
Reel/Frame 032651/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2012
From: SCHLEGL, ROBERT; MOHLEN, MICHAEL; WRUSS, JURGEN; WEBER, MICHAEL
To: INTERCELL AG
Reel/Frame 028358/0972 →